opb-51602
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2009 (NCT01184807)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
STAT3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- opb-51602
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02058017 | Phase 1 | Nov 1, 2013 | National University of Singapore, Otsuka, Shin Nippon Biomedical Laboratories |
| NCT01344876 | Phase 1 | Apr 1, 2011 | Otsuka |
| NCT01423903 | Phase 1 | Feb 1, 2010 | Otsuka |
| NCT01184807 | Phase 1 | Dec 1, 2009 | Government of Singapore, Otsuka |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 4 | 3 | 1 | 2009 |
| Government of Singapore | Government | 1 | 0 | 1 | 2009 |
| National University of Singapore | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Shin Nippon Biomedical Laboratories | For profit | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1